1215310-75-0

Basic information

• Product Name: 2-Formyl-5-(methylsulphonyl)benzotrifluoride, 4-Formyl-3-(trifluoromethyl)phenyl methyl sulphone
• Synonyms: 2-Formyl-5-(methylsulphonyl)benzotrifluoride, 4-Formyl-3-(trifluoromethyl)phenyl methyl sulphone;4-(Methylsulphonyl)-2-(trifluoromethyl)benzaldehyde;4-(Methylsulfonyl)-2-(trifluoroMethyl)benzaldehyde;2-Formyl-5-(methylsulphonyl)benzotrifluoride
• CAS NO: 1215310-75-0
• Molecular Formula: C₉H₇F₃O₃S
• Molecular Weight: 252.2102896
• Mol File: 1215310-75-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 381.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.429±0.06 g/cm3(Predicted)
• Vapor Pressure: 0-0.001Pa at 20-25℃
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Formyl-5-(methylsulphonyl)benzotrifluoride, 4-Formyl-3-(trifluoromethyl)phenyl methyl sulphone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Formyl-5-(methylsulphonyl)benzotrifluoride, 4-Formyl-3-(trifluoromethyl)phenyl methyl sulphone(1215310-75-0)
• EPA Substance Registry System: 2-Formyl-5-(methylsulphonyl)benzotrifluoride, 4-Formyl-3-(trifluoromethyl)phenyl methyl sulphone(1215310-75-0)

Safety Data

• Hazardous Substances Data: 1215310-75-0(Hazardous Substances Data)

Usage

General Description

The chemical "2-Formyl-5-(methylsulphonyl)benzotrifluoride, 4-Formyl-3-(trifluoromethyl)phenyl methyl sulphone" is a compound that consists of a benzotrifluoride ring with a formyl group and a methylsulphonyl group attached at positions 2 and 5, respectively. Additionally, it contains a trifluoromethyl group attached to a phenyl ring with a formyl group and a methyl sulphone group at positions 4 and 3, respectively. These chemicals are commonly used in organic synthesis and pharmaceutical research due to their unique properties and potential applications in drug development and material science.

Upstream product

• 20277-69-4 sodium methansulfinate 
• 90176-80-0 2-(trifluoromethyl)-4-fluorobenzaldehyde 

Downstream Products

• 934557-65-0 1-(bromomethyl)-4-(methylsulfonyl)-2-(trifluoromethyl)benzene 
• 872365-14-5 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridine-3-yl]acetic acid 
• 1215323-17-3 (4-(methylsulfonyl)-2-(trifluoromethyl)phenyl)methanol 

Relevant articles and documents

Fevipiprant selective prostaglandin DP2 (CRTh2) inhibitor treatment of asthma

Prostaglandin D2 (PGD2), a major prostanoid, releases from activated mast cells. It activates and recruits various inflammatory cells like eosinophils and basophils through DP2 receptors to the site of inflammation and further promotes late-phase allergic reactions. For the last decade, the scientific community has extensively explored this pathway and synthesized various specific DP2 receptor antagonists for the management of asthma. About 20 compounds with DP2 antagonistic activity have reached different stages of clinical development. Among these, fevipiprant is one of the most advanced oral DP2 inhibitors as it selectively blocks the DP2 receptors. Fevipiprant has demonstrated an acceptable safety profile in phase II studies as evident from significant reduction of moderate to severe asthma exacerbations. Currently this novel antiasthmatic drug is in phase III clinical trials. This review provides a brief overview of PGD2 blockers, particularly fevipiprant and its preclinical pharmacology and clinical development, by providing a summary of completed or ongoing clinical studies assessing its safety and efficacy in asthma.